Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003109 · ClinicalTrials.gov registry record · Phase 1
Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT00003109 is a Phase 1 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 39 participants.
The verdict
NCT00003109, a Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus raltitrexed in treating patients who have refractory solid tumors that have not responded to previous therapy.
Interventions
- DRUG irinotecan hydrochloride
- DRUG raltitrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 1997-12 |
| Est. Completion | 2001-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003109
The ClinicalTrials.gov registry entry for NCT00003109 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which irinotecan hydrochloride is the first listed.
NCT00003109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003109 about?
NCT00003109 is a clinical study titled "Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus raltitrexed in treating patients who have refractory s...
What is the current status of trial NCT00003109?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 1997-12. Estimated completion is 2001-01.
What interventions are being tested in trial NCT00003109?
The interventions under investigation include: irinotecan hydrochloride (DRUG), raltitrexed (DRUG).
Who is sponsoring clinical trial NCT00003109?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.